Neuren (NEU) – ASX Announcement 27 March 2025 Neuren initiates development of NNZ-2591 to treat HIE in newborns Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) announced the initiation of development ofNNZ-2591 to treat hypoxic-ischemic encephalopathy (HIE). HIE is a devastating type of brain injurycaused when a baby’s brain does not receive enough oxygen or blood flow before or shortly after birth.About two to three in every 1,000 births in high income countries and 10-30 per 1,000 births in low- andmiddle-income countries will be affected by HIE, which means that many thousands of babies andchildren experience HIE every year. It is one of the leading causes of neonatal death andneurodevelopmental disability worldwide.HIE can lead to a range of symptoms in surviving children, including developmental delays, cognitiveimpairment, cerebral palsy, and seizures. Some children develop serious long-term complications thatcan affect them well into adulthood. Currently, the only approved treatment for HIE is temporaryhypothermia (cooling the head or whole body to lower the baby’s metabolic rate and give the brainsome time to recover from the hypoxic event). Hypothermia provides a modest decrease in mortalityand severe neurodevelopmental disability, however even with hypothermia, 40-45% of children whosurvive HIE have significant neurodevelopmental impairment at 2 years of age.
NEU Price at posting:
$11.93 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)